Sales of shingles vaccines boosted GlaxoSmithKline Plc's profits in the final quarter of 2018, allaying investor concerns about Britain's biggest drugmaker's prospects beyond its blockbuster Advair asthma drug.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,